Collate Capital Launches to Support Early Stage Companies
NEW YORK, Jan. 8, 2020 /PRNewswire/ -- We are excited to announce the formation of Collate Capital, a technology-focused investment firm that will invest in promising early stage businesses in North America and Europe. Collate plans to fund the next generation of entrepreneurs that have businesses that are innovative, differentiated and ready to scale.
Collate follows the mantra of our namesake, which means to collect and combine. We want to empower entrepreneurs to succeed. We will bring the best team together to support founders and their strategy.
With a flexible mandate, Collate will invest up to $2 million (per investment) in technology, software, market infrastructure and consumer-based businesses. Collate's primary focus will be companies in seed to Series B rounds of financings.
Collate Capital was founded by Mark Weaver, an experienced investor who has spent his career successfully investing in a wide range of businesses and industries.
"We believe that our network of advisors, coupled with the value-added capital and partnership that we provide, will be attractive to the next generation of founders and entrepreneurs. We'd like to thank all of the family, friends, advisors, mentors and investors that helped us to reach this milestone today," said Weaver.
Data I/O Corporation , the leading global provider of advanced security and data deployment solutions for microcontrollers, security ICs and memory devices, today announced financial results for the first quarter ended March 31, 2024.
First Quarter...
SkyWest, Inc. ("SkyWest") today reported financial and operating results for Q1 2024, including net income of $60 million, or $1.45 per diluted share, compared to net loss of $22 million, or $0.45 loss per share, for Q1 2023.
Commenting on the...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...
Stevanato Group S.p.A. , a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first...
Bruker Corporation today announced it will report first quarter 2024 financial results before market opening on Thursday, May 2, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss the results and current...
Gilead Sciences, Inc. announced today its first quarter 2024 results of operations.
"Gilead delivered another strong quarter of revenue growth in the first quarter with 6% year-over-year growth in our base business driven by HIV, Oncology and...
